AI's growth is driving massive energy consumption, with data centers consuming vast amounts of electricity akin to small towns. Current energy infrastructure struggles to keep pace with AI's escalating demands,…
Granata Bio acquires Oviva Therapeutics, signaling a major development in women's health innovation. Oviva's breakthrough molecule, OVI-586, aims to extend ovarian function, offering new possibilities for menopause, contraception, and IVF.…
The biotech sector is a high-risk, high-reward arena, characterized by rapid breakthroughs and potential setbacks. Biotech ventures rely heavily on a synergy of cutting-edge science, securing regulatory approval, and gaining…
A pivotal leadership change occurs at Edesa Biotech as Peter J. Weiler is appointed CFO, bringing extensive experience in business development and pharmaceutical leadership. Weiler's background includes key roles at…
Wacker Biotech and RNAV8 Bio have joined forces to revolutionize mRNA engineering, transforming treatments for genetic and common diseases. Wacker Biotech specializes in producing high-quality mRNA and formulating lipid nanoparticles…
F-star Therapeutics is emerging as an independent biotech company following its $161 million acquisition by invoX Pharma, a subsidiary of Sino Biopharmaceutical. The acquisition faced regulatory challenges, particularly with the…
Abzena is at the forefront of innovation in bioconjugation and complex biologics, transforming drug development. Led by Dave Williamson, a former soldier turned Chief Information Officer, the company leverages big…
Chinese biotech companies are actively expanding internationally, increasing overseas collaborations by 18% in the first quarter. The companies have sealed 33 international partnerships, totaling $36.2 billion in transactions, showcasing their…
Travere Therapeutics, at a stock price of $19.68, has shown a promising 3.39% increase, indicating potential growth. Focused on rare disease therapies, Travere addresses critical medical needs with a unique…
Brensocatib, developed by Insmed Inc., is anticipated to revolutionize respiratory care for bronchiectasis patients. The drug has received FDA Priority Review, with a potential market launch in the third quarter…